Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: Activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway

Pediatric Research

Volumn 56, Issue 4, 2004, Pages 563-570

  Moreno, Laura ^a   Losada, Begoña ^a   Cogolludo, Angel L ^a   Lodi, Federica ^a   Lugnier, Claire ^b   Villamor, Eduardo ^c   Moro, Manuel ^a   Tamargo, Juan ^a   Pérez Vizcaíno, Francisco ^a,d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CNRS   (France)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CYCLIC GMP; DIPYRIDAMOLE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; ZAPRINAST;

ADOLESCENT; AGE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROLYSIS; LUNG ARTERY PRESSURE; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; SWINE; VASCULAR ENDOTHELIUM; VASODILATATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CYCLIC GMP; DIPYRIDAMOLE; MALE; NITRIC OXIDE; NITROPRUSSIDE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY ARTERY; PURINONES; SWINE; VASODILATION; VASODILATOR AGENTS;

EID: 4644299429     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000139412.58594.D0     Document Type: Article

References (39)

1. Fineman JR, Soifer SJ, Heymann MA 1995 Regulation of pulmonary vascular tone in the perinatal period. Annu Rev Physiol 57:115-134
2. Ziegler JW, Ivy DD, Kinsella JP, Abman SH 1995 The role of nitric oxide, endothelin, and prostaglandins in the transition of the pulmonary circulation. Clin Perinatol 22:387-403
3. Haworth SG, Hislop AA 1981 Adaptation of the pulmonary circulation to extra-uterine life in the pig and its relevance to the human infant. Cardiovasc Res 15:108-119
4. Morecroft I, MacLean MR 1998 Developmental changes in endothelium-dependent vasodilation and the influence of Superoxide anions in perinatal rabbit pulmonary arteries. Br J Pharmacol 125:1585-1593
5. Abman SH, Chatefield BA, Rodman DM, Hall SL, McMurtry IF 1991 Maturational changes in endothelium-derived relaxing factor activity of ovine pulmonary arteries in vitro. Am J Physiol 260:L280-L285
6. Shaul PW 1999 Regulation of vasodilator synthesis during lung development. Early Hum Dev 54:271-294
7. Villamor E, Perez-Vizcaino, Cogolludo AL, Conde-Oviedo J, Zaragoza-Arnaez F, Lopez-Lopez JG, Tamargo J 2000 Relaxant effects of carbon monoxide compared with nitric oxide in pulmonary and systemic vessels of newborn piglets. Pediatr Res 48:546-553
8. Pérez-Vizcaíno F, López-López JG, Santiago R, Cogolludo A, Zaragozá-Arnáez F, Moreno L, Alonso MJ, Salaíces M, Tamargo J 2002 Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung Cell Mol Physiol 283:L839-L848
9. Abman SH 1999 Abnormal vasoreactivity in the pathophysiology of persistent pulmonary hypertension of the newborn. Pediatr Rev 20:e103-e109
10. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA 2000 Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375-414
11. Francis SH, Turko IV, Corbin JD 2001 Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52
12. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA 2003 Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291
13. Giordano D, De Stefane ME, Citro G, Modica A, Giorgi M 2001 Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 1539:16-27
14. MacLean MR, Johnston ED, McCulloch KM, Pooley L, Houslay MD, Sweeney G 1997 Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 283:619-624
15. Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, Fineman JR 2001 sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 281:L1051-L1057
16. Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR 1998 Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 275:L931-L941
17. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F 2002 Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360:895-900
18. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR 2001 Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104:424-428
19. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S 2002 Oral Sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398-2403
20. Shekerdemian L, Ravn HB, Penny DJ 2002 Intravenous Sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 165:1098-1102
21. Oliver J, Webb DJ 2002 Sildenafil for "blue babies". Such unlicensed drug use might be justified as a last resort. BMJ 325:1174
22. Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, Clarke WR 1998 Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 158:279-288
23. Black SM, Johengen MJ, Soifer SJ 1998 Coordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in fetal lambs. Pediatr Res 44:821-830
24. Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, Bloch KD 1998 Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 43:163-168
25. Bina S, Hart JL, Sei Y, Muldoon SM 1998 Factors contributing to differences in the regulation of cGMP in isolated porcine pulmonary vessels. Eur J Pharmacol 351:253-260
26. Cortijo J, Naline E, Ortiz JL, Berto L, Girard V, Malbezin M, Advenier C, Morcillo EJ 1998 Effects of fenspiride on human bronchial cyclic nucleotide phosphodiesterase isoenzymes: functional and biochemical study. Eur J Pharmacol 341:79-86
27. Rousseau E, Gagnon J, Lugnier C 1994 Characterization of cyclic nucleotide phosphodiesterase isozymes in bovine airway epithelium. Mol Cell Biochem 140:171-175
28. Rousseau E, Dostie J, Taoudi-Benchekroun M, Cadieux A, Beaudry C, Lugnier C 1995 Specific cyclic nucleotide phosphodiesterase inhibitors differently modulate contractile kinetics in airway smooth muscle. Can J Physiol Pharmacol 73:1784-1794
29. Lopez-Lopez JG, Perez-Vizcaino F, Cogolludo AL, Ibarra M, Zaragoza-Arnáez F, Tamargo J 2001 Nitric oxide- and nitric oxide donors-induced relaxation and its modulation by oxidative stress in piglet pulmonary arteries. Br J Pharmacol 133:615-624
30. Keravis TM, Wells JN, Hardman JG 1980 Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. Biochim Biophys Acta 613:116-129
31. Pauvert O, Salvail D, Rousseau E, Lugnier C, Marthan E, Savineau JP 2002 Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 63:1763-1772
32. Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, Savineau JP 2003 Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br J Pharmacol 139:513-522
33. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA, Ferguson K 1998 Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216:139-147
34. Wu SN, Li HF, Chiang HT 2001 Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells. Biochem Pharmacol 61:877-892
35. Yan C, Zhao AZ, Bentley JK, Beavo JA 1996 The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem 271:25699-25706
36. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA 2002 Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277:3310-3317
37. Finer NN, Barrington KJ 2001 Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 4:CD000399
38. Reffelmann T, Kloner RA 2003 Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108:239-244
39. Shekerdemian LS, Ravn HB, Penny DJ 2004 Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 55:413-418